Per aspera ad astra: application of Simplex QSAR approach in antiviral research

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Patick AK. Rhinovirus chemotherapy. Antivir. Res.71,391–396 (2006).
  Medline CASGoogle Scholar
• 2  Rotbart HA. Treatment of picornavirus infections. Antivir. Res.53,83–98 (2002).
  Medline CASGoogle Scholar
• 3  Barnard DL. Current status of anti-picornavirus therapies. Curr. Pharm. Des.12,1379–1390 (2006).
  Medline CASGoogle Scholar
• 4  Prado-Pradoa FJ, Borgesa F, Uriarte E, Perez-Montoto LG, Gonzalez-Díaz H. Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. Analytica Chimica Acta651,159–164 (2009).
  MedlineGoogle Scholar
• 5  Binford SL, Maldonado F, Brothers MA et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother.49,619–626 (2005).
  Medline CASGoogle Scholar
• 6  Conti C, Mastromarino P, Goldoni P, Portalone G, Desideri N. Synthesis and anti-rhinovirus properties of fluoro-substituted flavonoids. Antivir. Chem. Chemother.16(4),267–276 (2005).
  Medline CASGoogle Scholar
• 7  Cutri CC, Garozzo A, Siracusa MA et al. Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum. Antivir. Res.55,357–368 (2002).
  Medline CASGoogle Scholar
• 8  Diana GD, Cutcliffe D, Oglesby RC et al. Synthesis and structure–activity studies of some disubstituted phenylisoxazoles against human picornavirus. J. Med. Chem.32,450–455 (1989).
  Medline CASGoogle Scholar
• 9  Dragovich PS, Prins TJ, Zhou R et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. J. Med. Chem.45,1607–1623 (2002).
  Medline CASGoogle Scholar
• 10  Gaudernak E, Seipelt J, Triendl A, Grassauer A, Kuechler E. Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses. J. Virol.76,6004–6015 (2002).
  Medline CASGoogle Scholar
• 11  Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antivir. Res.47,215–220 (2000).
  Medline CASGoogle Scholar
• 12  Ooms F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. Curr. Med. Chem.7(2),141–158 (2000).
  Medline CASGoogle Scholar
• 13  Mullin R. Drug development costs about $1.7 billion. Chem. Engineer. News50,8 (2003).
  Google Scholar
• 14  Thomas G. Medicinal Chemistry: An Introduction. Wiley, NY, USA 664 (2008).
  Google Scholar
• 15  Bailey TR, Diana GD, Kowalczyk PJ et al. Antirhinoviral activity of heterocyclic analogs of Win 54954. J. Med. Chem.35,4628–4633 (1992).
  Medline CASGoogle Scholar
• 16  Kuz’min VE, Artemenko AG, Lozitsky VP et al. The analysis of structure–anticancer and antiviral activity relationships for macrocyclic pyridinophanes and their analogues on the basis of 4D QSAR models (simplex representation of molecular structure). Acta Biochim. Polon.49,157–168 (2002).
  MedlineGoogle Scholar
• 17  Muratov EN, Artemenko AG, Kuz’min VE et al. Investigation of anti-influenza activity using hierarchic QSAR technology on the base of simplex representation of molecular structure. Antivir. Res.65(3),A62–A63 (2005).
  Google Scholar
• 18  Verma RP, Hansch C. Chemical toxicity on HeLa cells. Curr. Med. Chem.13(4),423–448 (2006).
  Medline CASGoogle Scholar
• 19  Jenssen H, Gutteberg TJ, Lejon T. Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. J. Pept. Sci.11(2),97–103 (2005).
  Medline CASGoogle Scholar
• 20  Teixeira C, Serradji N, Maurel F, Barbault F. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Eur. J. Med. Chem.44,3524–3532 (2009).
  Medline CASGoogle Scholar
• 21  Artemenko AG, Muratov EN, Kuz’min VE et al. Identification of individual structural fragments of N,N´-(bis-5-nitropyrimidyl)dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. J. Antimicrob. Chemother.60(1),68–77 (2007).
  Medline CASGoogle Scholar
• 22  Butina D, Gola JMR. Modeling aqueous solubility. J. Chem. Inf. Comp. Sci.43,837–841 (2004).
  Google Scholar
• 23  Kovatcheva A, Golbraikh A, Oloff S et al. Combinatorial QSAR of ambergris fragrance compounds. J. Chem. Inf. Comp. Sci.44,582–595 (2004).
  Medline CASGoogle Scholar
• 24  Kubinyi H. Quantitative structure–activity relationships (QSAR) and molecular modeling in cancer research. J. Cancer Res. Clin. Oncol.116,529–537 (1990).▪ One of the best reviews of ‘old-fashioned quantitative structure-activity relationship (QSAR)’.
  Medline CASGoogle Scholar
• 25  Kuz’min VE, Artemenko AG, Lozitska RN et al. Investigation of anticancer activity of macrocyclic Schiff bases by means of 4D-QSAR based on simplex representation of molecular structure. SAR QSAR Environ. Res.16(3),219–230 (2005).
  MedlineGoogle Scholar
• 26  Kuz’min VE, Artemenko AG, Muratov EN et al. Quantitative structure–activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives – human rhinovirus 2 replication inhibitors. J. Med. Chem.50,4205–4213 (2007).▪ Example of successful molecular design and mechanistic interpretation of Simplex representation of molecular structure (SiRMS) QSAR models.
  MedlineGoogle Scholar
• 27  Zhang S, Golbraikh A, Tropsha A. The development of quantitative structure-binding affinity relationship (QSBR) models based on novel geometrical chemical descriptors of the protein-ligand interfaces. J. Med. Chem.49,2713–2724 (2006).
  Medline CASGoogle Scholar
• 28  Selassie CD. History of QSAR. In: Burger’s Medicinal Chemistry and Drug Discovery, Abraham DJ (Ed.), Wiley, NY, USA, 1–48 (2003).▪ Interesting excursion to the origins of QSAR.
  Google Scholar
• 29  Cramer RD, Patterson DI, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape binding to carrier proteins. J. Am. Chem. Soc.110,5959–5967 (1988).
  Medline CASGoogle Scholar
• 30  Doweyko AM. The hypothetical active site lattice. An approach to modeling active sites from data on inhibitor molecules. J. Math. Chem.31,1396–1406 (1988).
  CASGoogle Scholar
• 31  Klebe G, Abraham U, Mietzner T. Molecular similarity indeces in comparative anaysis (CoMSIA) of molecules to correlate and predict their biological activity. J. Med. Chem.37,4130–4146 (1994).
  Medline CASGoogle Scholar
• 32  Kuz’min VE, Artemenko AG, Kovdienko NA, Tetko IV, Livingstone DJ. Lattice model for QSAR studies. J. Mol. Model.6,517–526 (2000).
  Google Scholar
• 33  Seel M, Turner DB, Wilett P. HQSAR–a highly predictive QSAR technique based on molecular holograms. QSAR18,245–252 (1999).
  CASGoogle Scholar
• 34  Robinson DD, Winn PJ, Lyne PD, Richards WG. Self-organizing molecular field analysis: a tool for structure-activity studies. J. Med. Chem.42,573–583 (1999).
  Medline CASGoogle Scholar
• 35  Pavan M, Consonni V, Gramatica P, Todeschini R. New QSAR modelling approach based on ranking models by genetic algorithms–variable subset selection (GA-VSS). In: Partial Order in Environmental Sciences and Chemistry, Springer, Berlin, Germany 181–217 (2006).
  Google Scholar
• 36  Baskin II, Hall LH, Palyulin VA, Zefirov NS. NASAWIN – a universal software for QSPR/QSAR studies. In: EuroQSAR 2002 Designing Drugs and Crop Protectants: processes, problems and solutions, Ford M (Ed.). Blackwell Publishing, NY, USA, 260–263 (2003).
  Google Scholar
• 37  Tropsha A, Golbraikh A. Predictive QSAR modeling workflow model applicability domains and virtual screening. Curr. Pharm. Des.13,3494–3504 (2007).
  Medline CASGoogle Scholar
• 38  Varnek A, Fourches D, Hoonacker F, Solov’ev VP. Substructural fragments: an universal language to encode reactions, molecular and supramolecular structures. J. Comp. Aid. Mol. Des.19,693–703 (2005).
  Medline CASGoogle Scholar
• 39  Todeschini R, Consonni V. Handbook of Molecular Descriptors. Wiley-VCH, Weinheim, Germany (2000).▪ Real handbook of molecular descriptors.
  Google Scholar
• 40  Kuz’min VE, Muratov EN, Artemenko AG, Gorb LG, Qasim M, Leszczynski J. The effect of nitroaromatics’ composition on their toxicity in vivo: novel, efficient non-additive 1D QSAR analysis. Chemosphere72,1373–1380 (2008).
  MedlineGoogle Scholar
• 41  Baurin N, Mozziconacci JC, Arnoult E, Chavatte P, Marot C, Morin-Allory L. 2D QSAR consensus prediction for high throughput virtual screening. An application to COX-2 inhibition modeling and screening of the NCI database. J. Chem. Inf. Model.44(1),276–285 (2004).
  CASGoogle Scholar
• 42  Vedani A, Dobler M. Multi-dimensional QSAR in drug design. Progress in Drug Res.55,107–135 (2000).
  Google Scholar
• 43  Tropsha A, Golbraikh A. Predictive quantitative structure–activity relationships modeling: data preparation and the general modelingworkflow. In: Handbook of Chemoinformatics Algorithms, Faulon J-L,Bender A (Ed.). Chapman and Hall London, UK, 175–212 (2010).
  Google Scholar
• 44  Kuz’min VE. About homo- and heterochirality of dissymetrical tetrahedrons (chiral simplexes). Stereochemical tunneling. Zh. Strucur. Khim.36,873–878 (1995).
  Google Scholar
• 45  Kuz’min VE, Artemenko AG, Muratov EN. Hierarchical QSAR technology on the base of Simplex representation of molecular structure. J. Comp. Aid. Mol. Des.22,403–421 (2008).
  MedlineGoogle Scholar
• 46  Burkert U, Allinger N. Molecular Mechanics. ACS Publication, Washington, DC, USA (1982).
  Google Scholar
• 47  Kubinyi H. Evolutionary variable selection in regression and PLS analyses. J. Chemometr.10,119–133 (1996).
  CASGoogle Scholar
• 48  Lindgren F, Geladi P, Rannar S, Wold S. Interactive variable selection (IVS) for PLS. Part 1: theory and algorithms. J. Chemometr.8,349–363 (1994).
  Google Scholar
• 49  Rannar S, Lindgren F, Geladi P, Wold S. A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: theory and algorithm. J. Chemometr.8,111–125 (1994).
  Google Scholar
• 50  Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure–activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comp. Sci.34(4),854–866 (1994).
  CASGoogle Scholar
• 51  Carhart RE, Smith DH, Venkataraghavan R. Atom pairs as molecular features in structure– activity studies. Definition and application. J. Chem. Inf. Comput. Sci.25,64–73 (1985).
  CASGoogle Scholar
• 52  Vitiuk NV, Kuz’min VE. Mechanistic models in chemometrics for the analysis of multidimensional data of researches. Analogue of dipole-moments method in the structure(composition)–property relationships analysis. Zh. Anal. Khimii49,165–167 (1994).
  Google Scholar
• 53  Kuz’min VE, Artemenko AG, Muratov EN et al. Virtual screening and molecular design based on hierarchical QSAR technology. In: Recent Advances in QSAR Studies. Puzyn T, Cronin M, Leszczynski J (Eds.). Springer, London, UK, 127–176 (2010).
  Google Scholar
• 54  Golbraikh A, Tropsha A. Beware of Q2. J. Mol. Graph. Model.20,269–276 (2002).▪ Turning point of predictive QSAR modeling.
  Medline CASGoogle Scholar
• 55  Muratov E, Varlamova E, Kuz’min V et al. Computer-aided drug design of novel anti-coxsackievirus b3 nancy agents by means of HiT QSAR. Antivir. Res.82,A61 (2009).
  Google Scholar
• 56  Zhang S, Golbraikh A, Oloff S, Kohn H, Tropsha A. A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR Models. J. Chem. Inf. Model.46,1984–1995 (2006).
  Medline CASGoogle Scholar
• 57  Kuz’min VE, Artemenko AG, Muratov EN et al. The hierarchical QSAR technology for effective virtual screening and molecular design of the promising antiviral compounds. Antivir. Res.65(3),A70-A71 (2005).
  Google Scholar
• 58  QSAR Expert Group. The report from the expert group on (quantitative) structure-activity relationships [(Q)SARs] on the principles for the validation of (Q)SARs. OECD Series on Testing and Assessment (ENV/JM/MONO[2004]24), 206 (2004).
  Google Scholar
• 59  Jaworska J, Nikolova-Jeliazkova N, Aldenberg T. QSAR applicability domain estimation by projection of the training set in descriptor space: a review. Altern. Lab. Anim.33,445–459 (2005).
  Medline CASGoogle Scholar
• 60  Östergard PRJ. A fast algorithm for the maximum clique problem. Discrete Appl. Math.120,195–205 (2002).
  Google Scholar
• 61  Muratov EN, Kuz’min VE, Artemenko AG et al. HiT QSAR analysis of anti-coxsackievirus B3 activity of [(biphenyloxy)propyl]isoxazole derivatives. Antivir. Res.78,A60–A61 (2008).
  MedlineGoogle Scholar
• 62  Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med. Res. Rev.20(1),58–101 (2000).
  Medline CASGoogle Scholar
• 63  Artemenko AG, Kuz’min VE, Muratov EN et al. Investigation of antiherpetic activity using hierarchic QSAR technology on the base of simplex representation of molecular structure. Antivir. Res.65(3),A77 (2005).
  Google Scholar
• 64  Sutherland JJ, O’Brien LA, Weaver DF. A comparison of methods for modeling quantitative structure-activity relationships. J. Med. Chem.47,5541–5554 (2004).
  Medline CASGoogle Scholar
• 65  Zhu H, Tropsha A, Fourches D et al. Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis. J. Chem. Inf. Model.48,766–784 (2008).
  Medline CASGoogle Scholar
• 66  Hansen K, Mika S, Schroeter T et al. Benchmark data set for in silico prediction of Ames mutagenicity. J. Chem. Inf. Model.49,2077–2081 (2009).
  Medline CASGoogle Scholar
• 67  Heritage TV, Ferguson AM, Turner DB, Willett P. EVA: a novel theoretical descriptor for QSAR studies Persp. Drug Disc. Des.11,381–398 (1998).
  Google Scholar
• 68  Polishchuk PG, Muratov EN, Artemenko AG, Kolumbin OG, Muratov NN, Kuz’min VE. Application of random forest approach to QSAR prediction of aquatic toxicity. J. Chem. Inf. Model.49,2481–2488 (2009).
  Medline CASGoogle Scholar
• 69  Hall LH, Kier LB. Electrotopological state indices for atom types – a novel combination of electronic, topological, and valence state information. J. Chem. Inf. Comp. Sci.35,1039–1045 (1995).
  CASGoogle Scholar
• 70  Katritzky AR, Oliferenko P, Oliferenko A, Lomaka A, Karelson M. Nitrobenzene toxicity: QSAR correlations and mechanistic interpretations. J. Phys. Org. Chem.16,811–817 (2003).
  CASGoogle Scholar
• 71  Cherkasov A. Can ‘bacterial-metabolite-likeness’ model improve odds of ‘in silico’ antibiotic discovery? J. Chem. Inf. Model.46,1214–1222 (2006).
  Medline CASGoogle Scholar
• 72  Martin TM, Harten P, Venkatapathy R, Das S, Young DM. A hierarchical clustering methodology for the estimation of toxicity. Toxicol. Mechanisms Methods18,251–266 (2008).
  Medline CASGoogle Scholar
• 73  Lagunin A, Zakharov A, Filimonov D, Poroikov V. A new approach to QSAR modelling of acute toxicity. SAR QSAR Env. Res.18,285–298 (2007).
  Medline CASGoogle Scholar
• 74  Filimonov D, Poroikov V, Borodina Y, Gloriozova T. Chemical similarity assessment through multilevel neighborhoods of atoms: definition and comparison with the other descriptors. J. Chem. Inf. Comp. Sci.39,666–670 (1999).
  CASGoogle Scholar
• 75  Artemenko A, Kuz’min V, Muratov E et al. Molecular design of active antiherpetic compounds using hierarchic QSAR technology. Antivir. Res.74,A76 (2007).
  Google Scholar
• 76  Muratov EN. Quantitative evaluation of the structural factors influence on the properties of nitrogen-, oxygen- and sulfur-containing macroheterocycles. National Academy of Sciences of Ukraine PhD Thesis 202 (2004).
  Google Scholar
• 77  Muratov EN, Kuz’min VE, Artemenko AG et al. QSAR studies on [(biphenyloxy)propyl]isoxazole derivatives with anti-rhinovirus 2 activity. Antivir. Res.74,A44 (2007).
  Google Scholar
• 78  Kuz’min V, Artemenko A, Muratov E et al. QSAR analysis of cytotoxicity in HeLa cells. Antivir. Res.78,A43 (2008).
  Google Scholar
• 79  Kuz’min V, Muratov E, Artemenko A et al. QSAR analysis of anti-coxsackievirus B3 Nancy activity of 2-amino-3-nitropyrazole[1,5-α]pyrimidines by means of simplex approach. Antivir. Res.74,A49–A50 (2007).
  Google Scholar
• 80  Muratov EN, Varlamova EV, Artemenko AG et al. QSAR analysis of [(biphenyloxy)propyl]isoxazoles – agents against coxsackievirus B3. J. Med. Chem.53 (2010) (In Press).
  Google Scholar
• 81  Kuz’min VE, Artemenko AG, Muratov EN et al. QSAR Analysis of anti-coxsackievirus B3 Nancy activity of 2-amino-3-nitropyrazole[1,5-α]pyrimidines by means of simplex approach. Antivir. Res.74,A49–A50 (2007).
  Google Scholar
• 82  Artemenko AG, Muratov EN, Kuz’min VE et al. Influence of artifical ribonucleases structure on their anti-HIV activity. Antivir. Res.70,A43 (2006).
  Google Scholar
• 83  Koroleva LS, Kuz’min VE, Muratov EN, Artemenko AG, Sil’nikov VN. Artificial ribonucleases: quantitative analysis of the structure– activity relationship and a new insight into the strategy of design of highly efficient RNAse mimetics. Bioorg. Khim.34,495–505 (2008).
  Medline CASGoogle Scholar
• 84  Kuz’min VE, Muratov EN, Artemenko AG, Sidzhakova D, Galabov AS. Antiviral activity of tetrahydro-2(1H)-pyrimidinones and related compounds: classification SAR study. Antivir. Res.2009(82),A61 (2009).
  Google Scholar
• 85  Galabov AS, Velichkova E, Karparov A, Sidzakova D, Danchev D, Chakova N. Antiviral activity of tetrahydro-2(1H)-pyrimidinones and related compounds. Arzneim. Forsch.34,9–14 (1984).
  Medline CASGoogle Scholar
• 86  Fourches D, Muratov EN, Tropsha A. Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model. DOI:10.1021/ci100176x (2010) (In Press).
  Google Scholar
• 87  Polanski J. Receptor dependent multidimensional QSAR for modeling drug receptor interactions. Curr. Med. Chem.16,3243–3257 (2009).
  Medline CASGoogle Scholar
• 88  Lill MA. Multi-dimensional QSAR in drug discovery. Drug Disc. Today12,1013–1017 (2007).
  Medline CASGoogle Scholar
• 89  Tropsha A. Recent advances in development, validation and exploitation of QSAR models. In: Burger’s Medicinal Chemistry and Drug Discovery, Abraham D (Ed.). John Wiley & Sons, Inc, NY, USA (2010) (In Press).▪ Well written review about good practices and recent trends in QSAR analysis.
  Google Scholar
• 90  Shakespeare W. The Tragedy of Hamlet, Prince of Denmarke. (Folio I). Act I, Sc. III (1623).
  Google Scholar
• 91  Shakespeare W. Hamlet. Barron’s Educational Series Inc, New York. 340 (2003).▪▪ One of the most powerful and influential tragedies ever written.
  Google Scholar
• 92  Hillebrecht A, Klebe G. Use of 3D QSAR models for database screening: a feasibility study. J. Chem. Inf. Model.48,384–396 (2008).
  Medline CASGoogle Scholar
• 93  Brown RD, Martin YC. The information content of 2D and 3D structural descriptors relevant to ligand-receptor binding. J. Chem. Inf. Comp. Sci.37,1–9 (1997).
  CASGoogle Scholar
• 94  Gedeck P, Rohde B, Bartels C. QSAR – how good is it in practice? Comparison of descriptor sets on an unbiased cross section of corporate data sets. J. Chem. Inf. Model.46,1924–1936 (2006).
  Medline CASGoogle Scholar
• 95  Kuz’min VE, Muratov EN, Artemenko AG et al. Consensus QSAR modeling of phosphor-containing chiral AChE inhibitors. QSAR Comb. Sci.28,664–677 (2009).
  Google Scholar
• 96  Nikolaeva L, Galabov AS. In vitro inhibitor effects of dual combinations of picornavirus replication inhibitors. Acta Virologica43,303–311 (1999).
  Medline CASGoogle Scholar
• 97  Muratov EN, Varlamova EV, Kuz’min VE, Artemenko AG, Nikolaeva-Glomb L, Galabov AS. QSAR analysis of poliovirus inhibition by dual combinations of antivirals. Antivir. Res. DOI:10.1016/j.antiviral.2010.02.456 (2010) (Epub ahead of print).
  Google Scholar
• 98  Muratov EN, Kuz’min VE, Artemenko AG. Domain applicability: how far are ideal and reality? Presented at: Model Applicability Domains: When Can I Use My Model? Symposium on the 235th ACS National Meeting. New Orleans, USA, 6–10 April 2008.
  Google Scholar
• 99  Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A. Chemoinformatics analysis of assertions describing drug-induced liver injury in different species. Chem. Res. Toxicol.23,171–183 (2010).▪ One of very few examples of how developed QSAR models were successfully used for the correction of misannotated compounds in chemical databases.
  Medline CASGoogle Scholar